Table 2 Univariate and multivariate analysis of TS-score correlating with pCR in primary cohort.

From: Predicting neoadjuvant chemotherapy benefit using deep learning from stromal histology in breast cancer

Factors

Univariate analysis

Multivariate analysisa

Multivariate analysisb

OR(95% CI)

P

OR(95% CI)

P

OR(95% CI)

P

TS-score

–

<0.001

–

–

–

<0.001

Subtypes

–

<0.001

–

<0.001

–

<0.001

HR+/HER2−

1

–

1

–

1

–

HER2+

9.28 (5.91–14.6)

<0.001

7.47 (4.66–12.0)

<0.001

7.73 (4.76–12.5)

<0.001

TNBC

5.21 (3.04–8.93)

<0.001

3.73 (2.10–6.62)

<0.001

3.33 (1.86–5.97)

<0.001

sTILs

–

<0.001

–

<0.001

–

0.766

Low

1

–

1

–

1

–

Moderate

7.58 (4.00–14.4)

<0.001

1.76 (1.16–2.69)

0.009

1.03 (0.64–1.66)

0.905

High

2.78 (1.47–5.25)

0.002

4.58 (2.20–9.54)

<0.001

1.36 (0.57–3.27)

0.490

cT

0.61 (0.43–0.86)

0.005

0.73 (0.49–1.10)

0.130

0.77 (0.51–1.16)

0.204

Ki67

2.63 (1.40–4.94)

0.003

1.40 (0.69–2.81)

0.348

1.19 (0.58–2.46)

0.636

NG

2.59 (1.80–3.70)

<0.001

1.37 (0.91–2.07)

0.137

1.21 (0.79–1.85)

0.372

  1. Multivariate analysis arefers to the multivariate analysis excluding TS-score; Multivariate analysis brefers to the multivariate analysis including the TS-score.
  2. TS-score tumor-stroma score, HR hormone receptor, HER2 human epidermal growth factor receptor 2, sTILs stromal tumor-infiltrating lymphocytes, NG nuclear grade.
Back to article page